Clinical Trial Update: Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating metronomic vinorelbine in combination with lapatinib for HER2-positive metastatic breast cancer; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Navelbine (vinorelbine)
• Tykerb (lapatinib)

Snippet

Sponsor: University Hospital of Crete | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED